Synapse - Hematologic Malignancies, Division of

Results (170)

Impact of recent translational and therapeutic developments on clinical course of BCR::ABL1-positive and -negative myeloproliferative neoplasms

Review

Mughal, T. I.; Mascarenhas, J.; Rampal, R. K.; Bose, P.; Lion, T.; Ajufo, H.; Yacoub, A.; Meshinchi, S.; Masarova, L.; Mesa, R.; more...
Hematological Oncology (2025)

Fulltext@MSK | Save

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital

Research Letter

Le Lan, C.; Belot, A.; Golfier, C.; Audin, B.; Sesques, P.; Bernier, A.; Safar, V.; Ferrant, E.; Lazareth, A.; Lequeu, H.; more...
Hematological Oncology (2024)

Fulltext@MSK | Save

TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO‐CEL) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)

Meeting Abstract

Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia‐Sancho, A. M.; Reguera Ortega, J. L.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 3 trial of subcutaneous epcoritamab + R‐CHOP versus R‐CHOP in patients (pts) with newly diagnosed diffuse large B‐cell lymphoma (DLBCL): EPCORE DLBCL‐2

Meeting Abstract

Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M. R.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer‐Glusman, E.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Lisocabtagene maraleucel (LISO‐CEL) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design transcend NHL 001 study

Meeting Abstract

Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Daratumumab and EPOCH for HIV+/‐ plasmablastic lymphoma: A feasibility study of the AIDS Malignancy Consortium (AMC 105)

Meeting Abstract

Noy, A.; Barta, S. K.; Tan, C. R.; Kwon, D.; Baiocchi, R.; Rubinstein, P.; Ambinder, R.
Hematological Oncology (2023)

Fulltext@MSK | Save

ZUMA‐24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B‐cell lymphoma given outpatient with corticosteroids

Meeting Abstract

Leslie, L.; Tees, M.; Flinn, I. W.; Rodriguez, T. E.; Baird, J. H.; Deol, A.; Mead, M.; Bachier, C.; Rapoport, A. P.; McClune, B.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas

Meeting Abstract

Imber, B. S.; Yahalom, J.; Palomba, M. L.
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies

Meeting Abstract

Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 1 trial of KT‐333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

Meeting Abstract

Smith, S.; Olszewski, A.; Starodub, A. N.; Stevens, D. A.; Feldman, T.; Porcu, P.; Epstein-Peterson, Z.; Huen, A.; Pinter‐Brown, L.; Mattour, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save